为了加强女性健康市场地位, 曼金德制药公司以13,630亿卢比收购了Bharat血清和疫苗. Mankind Pharma acquires Bharat Serums and Vaccines for ₹13,630 crore to bolster women's health market position.

Mankind Pharma 宣布以 1363 亿卢比（12 亿美元）收购 Bharat Serums and Vaccines 后，股价上涨 3.1%。 Mankind Pharma's shares rose 3.1% following its announcement to acquire Bharat Serums and Vaccines for ₹13,630 crore ($1.2 billion). 公司计划通过非可转换债券和短期商业证券筹集超过9,000亿卢比,平均成本为8.5%. To finance this, the company plans to raise over ₹9,000 crore through non-convertible debentures and short-term commercial paper at an average cost of 8.5%. 这一收购将加强人类在妇女保健市场中的地位,目标是20%的市场份额。 This acquisition will bolster Mankind's position in the women’s health market, targeting a 20% market share. 预计3-4个月后完成。 Completion is expected in 3-4 months.